Pharmaceutical care and analysis of treatment plan on severe immune pneumonia caused by pembrolizumab
Objective To discuss the mechanism and treatment of immune pembrolizumab caused by pabolizumab,so as to optimize the treatment plan for patients and ensure the safety and effectiveness of medication.Methods Clinical pharmacists participated in the treatment of severe immune-related pneumonia caused by immune checkpoint inhibitor pembrolizumab in a patient with lung cancer.By combing the treatment process and analyzing the causes of adverse reactions,provide high-quality suggestions for the follow-up treatment plan of the patient,and provide pharmaceutical care suggestions for the patient.Results Immune pneumonia is a adverse reaction of pembrolizumab injection and its occurrence is related to immune tolerance imbalance.The patient has grade 3 adverse reactions,immunotherapy should be stopped permanently.For the patient who fail immunotherapy,in order to prevent rapid tumor progression,chemotherapy,anti vascular and other treatment methods should be used immediately.Conclusion By participating in the analysis of the occurrence mechanism and treatment measures of the patient's immune pneumonia,the clinical pharmacist provides medication reference and guidance for the patient undergoing immunotherapy and provides pharmaceutical care to improve the effectiveness and safety of drug treatment.
PembrolizumabImmuno-associated pneumoniaPharmaceutical careAnalysis of treatment
万方数据
维普
